ERIS Lifesciences Ltd Share Price – NSE /  BSE

Pharmaceuticals, Small Cap

Net profit of ERIS Lifesciences rose 31.23% to Rs 120.19 crore in the quarter ended September 2025 as against Rs 91.59 crore during the previous quarter ended September 2024. Sales rose 6.93% to Rs 790.15 crore in the quarter ended September 2025 as against Rs 738.95 crore during the previous quarter ended September 2024.

Powered by Capital Market - Live News

ERIS Lifesciences will hold a meeting of the Board of Directors of the Company on 12 November 2025.

Powered by Capital Market - Live News

Eris Lifesciences has allotted 6,761 equity shares under ESOP on 30 August 2025. The paid-up share capital of the Company accordingly stands increased from Rs. 13,62,06,793/- (13,62,06,793 equity shares of Re. 1/- each) to Rs. 13,62,13,554/- (13,62,13,554 equity shares of Re. 1/- each).

Powered by Capital Market - Live News

Eris Lifesciences announced that one of its sterile injectable manufacturing facilities in Ahmedabad has received approval from Anvisa, Brazil's national health regulatory agency. This facility is part of subsidiary Swiss Parenterals that was acquired by Eris in 2024.

The approval follows a successful inspection conducted by the regulatory agency in April 2025 of both the injectable facilities of Swiss Parenterals, and the company expects to receive approval for the second facility soon. Both facilities are already EU GMP and PIC/s approved and supply a range of products to several Latin American markets including Mexico, Chile, Argentina and Peru. A company spokesperson said that the Anvisa approval would enable the company to launch its products in Brazil and achieve comprehensive coverage of the Latin American pharma market.

Commenting on the development, Amit Bakshi, CMD of Eris said, 'We take this approval as yet another endorsement of our operating and quality standards in life-saving dosage forms like injectables. This approval takes us a step forward in our strategic transformation into a company with increasing focus and leadership in complex injectables and biotechnology. We made major investments to initiate this transformation last year and we are glad to note that we have made significant progress in creating value from these investments with many more exciting developments expected in the quarters to come.?

Powered by Capital Market - Live News